- Home
- BJRI vs CGEM Comparison
BJRI vs CGEM Comparison
Compare BJRI & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BJRI | CGEM |
|---|---|---|
| Founded | 1978 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 706.6M | 671.7M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BJRI | CGEM |
|---|---|---|
| Price | $37.25 | $10.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $37.67 | $27.14 |
| AVG Volume (30 Days) | 543.3K | ★ 1.2M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.21 | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $1,388,066,000.00 | N/A |
| Revenue This Year | $5.14 | N/A |
| Revenue Next Year | $2.80 | N/A |
| P/E Ratio | $28.63 | ★ N/A |
| Revenue Growth | ★ 3.85 | N/A |
| 52 Week Low | $28.46 | $5.68 |
| 52 Week High | $47.02 | $13.78 |
Technical Indicators
Market Signals| Indicator | BJRI | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 57.87 | 60.08 |
| Support Level | $33.81 | $8.52 |
| Resistance Level | $38.97 | $13.33 |
| Average True Range (ATR) | 1.36 | 1.05 |
| MACD | 0.11 | 0.27 |
| Stochastic Oscillator | 64.83 | 56.74 |
Price Performance
Historical ComparisonAbout BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.